A 32-year-old man with schizophrenia has been on haloperidol 10 mg/day for 3 months. He now presents with involuntary orofacial movements, tongue protrusion, and lip smacking that persist even after dose reduction. His symptoms worsen with stress and improve during sleep. What is the most appropriate next step in management?

## Clinical Diagnosis The patient presents with **tardive dyskinesia (TD)** — involuntary choreiform movements of the orofacial region, tongue, and lips that: - Develop after prolonged antipsychotic exposure (≥3 months typical antipsychotics) - Persist or worsen after dose reduction - Improve during sleep and worsen with emotional stress - Are caused by dopamine receptor supersensitivity in the basal ganglia ## Management of Tardive Dyskinesia **Key Point:** Once TD develops on a first-generation antipsychotic (FGA), the gold standard is **switching to a second-generation antipsychotic (SGA)**, particularly those with lower D~2~ receptor occupancy and faster dissociation kinetics (quetiapine, clozapine). **High-Yield:** SGAs have a lower risk of causing or worsening TD because they: - Have shorter D~2~ receptor binding duration - Show preferential limbic over striatal dopamine blockade - May even improve existing TD in some cases ## Why Other Options Fail | Option | Why Wrong | |--------|----------| | Continue haloperidol + benztropine | Anticholinergics worsen TD; continuing the offending agent perpetuates the problem | | Increase haloperidol dose | Dose escalation exacerbates TD by increasing dopamine blockade and receptor supersensitivity | | Add propranolol | Beta-blockers are not evidence-based for TD; they may help akathisia but not orofacial dyskinesia | **Clinical Pearl:** Clozapine is the most effective SGA for TD reversal, but quetiapine or aripiprazole are reasonable alternatives if clozapine is contraindicated (requires agranulocytosis monitoring). **Warning:** Never increase or maintain FGA dose in established TD — this is a cardinal error in management.